Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcripts
Fiscal Year 2026
-
Horizon transformation will streamline operations, reduce costs, and focus on scientific and commercial excellence, targeting EUR 75 million in savings by 2027 and a 20% EBITDA margin by 2028. 2026 is a transition year, with market recovery and operational improvements expected to drive growth from 2027.
Fiscal Year 2025
-
Delivered strong Q4 growth and high-end full-year results in 2025, driven by Just - Evotec Biologics and strategic partnerships. Horizon transformation and commercial reorganization set the stage for margin expansion and sustainable growth, with 2026 as a transition year.
-
Group revenues declined 7% year-over-year to EUR 535.1 million, driven by a 12% drop in DNPD, while biologics grew 11% and secured a major Sandoz deal worth over $650 million. Cost reduction initiatives are ahead of plan, and the company confirmed 2025 guidance with improved free cash flow and a shift to a higher-margin, asset-light model.
-
H1 2025 saw group revenues decline 5% year-over-year, with D&PD down 11% and JEB up 16%. Strategic focus shifted to an asset-light, higher-margin model, highlighted by the planned €300M sale of J.POD Toulouse to Sandoz. Full-year guidance and midterm growth targets remain on track.
-
The presentation outlined a renewed strategic focus on innovation, operational excellence, and capital efficiency, with a shift toward integrated, success-sharing partnerships. Despite near-term market challenges, robust technology platforms and a strong pipeline position the company for above-market growth and improved margins by 2028.
-
Q1 2025 revenues declined 4% year-over-year to EUR 200 million, with shared R&D underperforming but Just Evotec Biologics exceeding expectations. Cost-saving measures are on track, guidance for 2025 is reaffirmed, and strong technology-driven collaborations continue to drive future growth.
Fiscal Year 2024
-
2024 saw modest revenue growth and strong Q4 results, with Just - Evotec Biologics driving expansion and cost-saving measures improving profitability. 2025 guidance anticipates 5%-10% revenue growth, continued operational discipline, and further investment in high-value, tech-driven segments.
-
2024 saw flat revenues overall, with strong growth in Biologics offsetting softness in Shared R&D. Cost-saving initiatives and new strategic partnerships are driving improved margins and liquidity, with a substantial Q4 profit uplift expected. Guidance for 2024 is confirmed.
-
H1 2024 saw modest revenue growth driven by Just – Evotec Biologics, but profitability was impacted by high fixed costs and a challenging market, prompting a strategic reset and cost-saving measures. Full-year guidance was revised downward, with recovery expected in 2025.